Multiple myeloma is an incurable hematologic cancer involving a type of white blood cell called plasma cells. Current therapies only have a palliative impact on the disease.
Since 2008, the Multiple Myeloma Research Unit team has participated in over 30 international and national clinical trials on various multiple myeloma therapies. Many of these studies have led to the approval of new drugs that are now available as standard treatment to improve care for multiple myeloma patients.
New therapeutic modalities being developed hold great promise for improving survival rates and quality of life for patients with this disease. Immunotherapy even has the potential to be a cure.
In collaboration with the Hematopoietic Stem Cell Transplantation research team, the Multiple Myeloma research team has developed original studies on allogeneic transplantation and the treatment of multiple myeloma associated with a potential cure.